TY - JOUR
T1 - Hippocampal expression of murine TNF results in attenuation of amyloid deposition in vivo
AU - Chakrabarty, Paramita
AU - Herring, Amanda
AU - Ceballos-Diaz, Carolina
AU - Das, Pritam
AU - Golde, Todd E.
N1 - Funding Information:
This work was supported by Mayo Clinic (TEG), National Institutes of Health/ National Institute on Aging Grants (RO1AG18454, RO1AG29886, P01AG25531; TEG) and American Health Assistance Foundation Grant A2009061 (PD).
PY - 2011
Y1 - 2011
N2 - Fibrillar amyloid (fA) peptide is the major component of A plaques in the brains of Alzheimer's disease (AD) patients. Inflammatory mediators have previously been proposed to be drivers of A pathology in AD patients by increasing amyloidogenic processing of APP and promoting A accumulation, but recent data have shown that expression of various inflammatory cytokines attenuates A pathology in mouse models. In an effort to further study the role of different inflammatory cytokines on A pathology in vivo, we explored the effect of murine Tumor Necrosis Factor (mTNF) in regulating A accumulation. Recombinant adeno-associated virus serotype 1 (AAV2/1) mediated expression of mTNF in the hippocampus of 4 month old APP transgenic TgCRND8 mice resulted in significant reduction in hippocampal A burden. No changes in APP levels or APP processing were observed in either mTNF expressing APP transgenic mice or in non-transgenic littermates. Analysis of A plaque burden in mTNF expressing mice showed that even after substantial reduction compared to EGFP expressing age-matched controls, the A plaque burden levels of the former do not decrease to the levels of 4 month old unmanipulated mice. Taken together, our data suggests that proinflammatory cytokine expression induced robust glial activation can attenuate plaque deposition. Whether such an enhanced microglial response actually clears preexisting deposits without causing bystander neurotoxicity remains an open question.
AB - Fibrillar amyloid (fA) peptide is the major component of A plaques in the brains of Alzheimer's disease (AD) patients. Inflammatory mediators have previously been proposed to be drivers of A pathology in AD patients by increasing amyloidogenic processing of APP and promoting A accumulation, but recent data have shown that expression of various inflammatory cytokines attenuates A pathology in mouse models. In an effort to further study the role of different inflammatory cytokines on A pathology in vivo, we explored the effect of murine Tumor Necrosis Factor (mTNF) in regulating A accumulation. Recombinant adeno-associated virus serotype 1 (AAV2/1) mediated expression of mTNF in the hippocampus of 4 month old APP transgenic TgCRND8 mice resulted in significant reduction in hippocampal A burden. No changes in APP levels or APP processing were observed in either mTNF expressing APP transgenic mice or in non-transgenic littermates. Analysis of A plaque burden in mTNF expressing mice showed that even after substantial reduction compared to EGFP expressing age-matched controls, the A plaque burden levels of the former do not decrease to the levels of 4 month old unmanipulated mice. Taken together, our data suggests that proinflammatory cytokine expression induced robust glial activation can attenuate plaque deposition. Whether such an enhanced microglial response actually clears preexisting deposits without causing bystander neurotoxicity remains an open question.
UR - http://www.scopus.com/inward/record.url?scp=79951551206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951551206&partnerID=8YFLogxK
U2 - 10.1186/1750-1326-6-16
DO - 10.1186/1750-1326-6-16
M3 - Article
C2 - 21324189
AN - SCOPUS:79951551206
SN - 1750-1326
VL - 6
JO - Molecular neurodegeneration
JF - Molecular neurodegeneration
IS - 1
M1 - 16
ER -